[HTML][HTML] Progress of potential drugs targeted in lipid metabolism research
K Liang, JY Dai - Frontiers in Pharmacology, 2022 - frontiersin.org
Lipids are a class of complex hydrophobic molecules derived from fatty acids that not only
form the structural basis of biological membranes but also regulate metabolism and maintain …
form the structural basis of biological membranes but also regulate metabolism and maintain …
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
JM McKenney - American journal of health-system pharmacy, 2005 - academic.oup.com
Purpose. The chemistry, pharmacology, pharmacokinetics, drug interactions, clinical
efficacy, adverse effects, dosage and administration, and place in therapy of rosuvastatin are …
efficacy, adverse effects, dosage and administration, and place in therapy of rosuvastatin are …
Myotoxicity associated with lipid-lowering drugs
AN Baer, RL Wortmann - Current opinion in rheumatology, 2007 - journals.lww.com
Myotoxicity associated with lipid-lowering drugs : Current Opinion in Rheumatology Myotoxicity
associated with lipid-lowering drugs : Current Opinion in Rheumatology Log in or Register …
associated with lipid-lowering drugs : Current Opinion in Rheumatology Log in or Register …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
MT Cooney, E Bruckert, A Cordero, A Corsini… - European Heart …, 2016 - iris.unime.it
The content of these European Society of Cardiology (ESC) and European Atherosclerosis
Society Guidelines has been published for personal and educational use only. No …
Society Guidelines has been published for personal and educational use only. No …
[PDF][PDF] Wytyczne ESC/EAS dotyczace leczenia zaburzeń lipidowych w 2016 roku
AL Catapano, I Graham, G De Backer, O Wiklund… - Kardiologia …, 2016 - air.unimi.it
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin …
CJ Glueck, D Aregawi, M Agloria, Q Khalil… - Clinical …, 2006 - Elsevier
BACKGROUND:: Patients with high levels of low-density lipoprotein cholesterol (LDL-C)
might not tolerate 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) …
might not tolerate 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) …
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins
GT Generaux, FM Bonomo, M Johnson… - Xenobiotica, 2011 - Taylor & Francis
Statins are the preferred class of drugs for treating patients with atherosclerosis and related
coronary heart disease. Treatment with statins leads to significant low-density lipoprotein …
coronary heart disease. Treatment with statins leads to significant low-density lipoprotein …
Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin
AL Catapano - Current vascular pharmacology, 2012 - ingentaconnect.com
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely
prescribed therapeutic class of drugs worldwide, with established clinical benefits both in …
prescribed therapeutic class of drugs worldwide, with established clinical benefits both in …
Alirocumab for the treatment of hypercholesterolemia
B Tomlinson, M Hu, Y Zhang, P Chan… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Alirocumab is a human monoclonal antibody inhibiting proprotein convertase
subtilisin/kexin type 9 (PCSK9) that is administered by subcutaneous injection every 2 …
subtilisin/kexin type 9 (PCSK9) that is administered by subcutaneous injection every 2 …
Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke …
TN Turan, MJ Lynn, A Nizam, B Lane… - … Quality and Outcomes, 2012 - Am Heart Assoc
e52 Circ Cardiovasc Qual Outcomes September 2012 investigator-initiated and designed
Phase III randomized, multicenter trial funded by the National Institute of Neurological …
Phase III randomized, multicenter trial funded by the National Institute of Neurological …